A comprehensive review in The Journal of Clinical Investigation finds no overall link between GLP-1 receptor agonists and increased cancer risk, countering early safety concerns. Instead, evidence suggests possible protective effects for certain cancers, supported by metabolic and immune-modulating mechanisms.
More...